메뉴 건너뛰기




Volumn 374, Issue 9690, 2009, Pages 590-592

The unchanging mortality gap for people with schizophrenia

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE;

EID: 68949101413     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61072-2     Document Type: Note
Times cited : (38)

References (11)
  • 1
    • 68949172254 scopus 로고    scopus 로고
    • 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)
    • 10.1016/S0140-6736(09)60742-X published online July 13, 2009.
    • Tiihonen J., Lönnqvist J., Wahlbeck K., et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet (2009) 10.1016/S0140-6736(09)60742-X published online July 13, 2009.
    • (2009) Lancet
    • Tiihonen, J.1    Lönnqvist, J.2    Wahlbeck, K.3
  • 2
    • 0032751075 scopus 로고    scopus 로고
    • Antipsychotic-induced weight gain: a comprehensive research synthesis
    • Allison D.B., Mentore J.L., Heo M., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156 (1999) 1686-1696
    • (1999) Am J Psychiatry , vol.156 , pp. 1686-1696
    • Allison, D.B.1    Mentore, J.L.2    Heo, M.3
  • 3
    • 0036213607 scopus 로고    scopus 로고
    • Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia
    • Sernyak M.J., Leslie D.L., Alarcon R.D., Losonczy M.F., and Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 159 (2002) 561-566
    • (2002) Am J Psychiatry , vol.159 , pp. 561-566
    • Sernyak, M.J.1    Leslie, D.L.2    Alarcon, R.D.3    Losonczy, M.F.4    Rosenheck, R.5
  • 4
    • 0036774640 scopus 로고    scopus 로고
    • Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database
    • Gianfrancesco F.D., Grogg A.L., Mahmoud R.A., Wang R.H., and Nasrallah H.A. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 63 (2002) 920-930
    • (2002) J Clin Psychiatry , vol.63 , pp. 920-930
    • Gianfrancesco, F.D.1    Grogg, A.L.2    Mahmoud, R.A.3    Wang, R.H.4    Nasrallah, H.A.5
  • 5
    • 43049092201 scopus 로고    scopus 로고
    • Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1
    • Meyer J.M., Davis V.G., Goff D.C., et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res 101 (2008) 273-286
    • (2008) Schizophr Res , vol.101 , pp. 273-286
    • Meyer, J.M.1    Davis, V.G.2    Goff, D.C.3
  • 6
    • 47249104183 scopus 로고    scopus 로고
    • Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1
    • Meyer J.M., Davis V.G., McEvoy J.P., et al. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophr Res 103 (2008) 104-109
    • (2008) Schizophr Res , vol.103 , pp. 104-109
    • Meyer, J.M.1    Davis, V.G.2    McEvoy, J.P.3
  • 7
    • 54849381700 scopus 로고    scopus 로고
    • Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study
    • Daumit G.L., Goff D.C., Meyer J.M., et al. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res 105 (2008) 175-187
    • (2008) Schizophr Res , vol.105 , pp. 175-187
    • Daumit, G.L.1    Goff, D.C.2    Meyer, J.M.3
  • 8
    • 34248562315 scopus 로고    scopus 로고
    • Antipsychotic medications: metabolic and cardiovascular risk
    • Newcomer J.W. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 68 suppl 4 (2007) 8-13
    • (2007) J Clin Psychiatry , vol.68 , Issue.SUPPL. 4 , pp. 8-13
    • Newcomer, J.W.1
  • 9
    • 67349119802 scopus 로고    scopus 로고
    • UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study)
    • Barnett A.H., Millar H.L., Loze J.Y., L'Italien G.J., van Baardewijk M., and Knapp M. UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study). Eur Arch Psychiatry Clin Neurosci 259 (2009) 239-247
    • (2009) Eur Arch Psychiatry Clin Neurosci , vol.259 , pp. 239-247
    • Barnett, A.H.1    Millar, H.L.2    Loze, J.Y.3    L'Italien, G.J.4    van Baardewijk, M.5    Knapp, M.6
  • 10
    • 33750061308 scopus 로고    scopus 로고
    • Clozapine utilization and outcomes by race in a public mental health system: 1994-2000
    • Kelly D.L., Dixon L.B., Kreyenbuhl J.A., et al. Clozapine utilization and outcomes by race in a public mental health system: 1994-2000. J Clin Psychiatry 67 (2006) 1404-1411
    • (2006) J Clin Psychiatry , vol.67 , pp. 1404-1411
    • Kelly, D.L.1    Dixon, L.B.2    Kreyenbuhl, J.A.3
  • 11
    • 33748768220 scopus 로고    scopus 로고
    • Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia
    • Lewis S.W., Barnes T.R., Davies L., et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 32 (2006) 715-723
    • (2006) Schizophr Bull , vol.32 , pp. 715-723
    • Lewis, S.W.1    Barnes, T.R.2    Davies, L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.